Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 346

1.
2.
3.

Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.

Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.

Cancer Res. 1996 Feb 1;56(3):556-62.

4.

Role of wild-type p53 in the enhancement of camptothecin cytotoxicity against human prostate tumor cells.

Arah IN, Song K, Seth P, Cowan KH, Sinha BK.

Anticancer Res. 1998 May-Jun;18(3A):1845-9.

PMID:
9673414
5.

Combination effect of adenovirus-mediated pro-apoptotic bax gene transfer with cisplatin or paclitaxel treatment in ovarian cancer cell lines.

Tsuruta Y, Mandai M, Konishi I, Kuroda H, Kusakari T, Yura Y, Hamid AA, Tamura I, Kariya M, Fujii S.

Eur J Cancer. 2001 Mar;37(4):531-41.

PMID:
11267864
6.

Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.

Kolfschoten GM, Hulscher TM, Schrier SM, van Houten VM, Pinedo HM, Boven E.

Gynecol Oncol. 2002 Mar;84(3):404-12.

PMID:
11855878
8.

Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.

Wen SF, Xie L, McDonald M, DiGiacomo R, Chang A, Gurnani M, Shi B, Liu S, Indelicato SR, Hutchins B, Nielsen LL.

Cancer Gene Ther. 2000 Nov;7(11):1469-80.

9.

Wild-type p53 gene transfection in human cultured sarcomas: effect of CDDP.

Endo K, Kuratate I, Watanabe M, Yoshida H, Teshima R, Osaki M, Ito H.

Oncol Rep. 2001 May-Jun;8(3):637-42.

PMID:
11295094
10.

WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.

Cuddihy AR, Jalali F, Coackley C, Bristow RG.

Mol Cancer Ther. 2008 Apr;7(4):980-92. doi: 10.1158/1535-7163.MCT-07-0471.

11.

Oncolytic herpes simplex virus-1 lacking ICP34.5 induces p53-independent death and is efficacious against chemotherapy-resistant ovarian cancer.

Coukos G, Makrigiannakis A, Kang EH, Rubin SC, Albelda SM, Molnar-Kimber KL.

Clin Cancer Res. 2000 Aug;6(8):3342-53.

12.

The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma.

Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ.

Cancer Res. 1996 May 1;56(9):2178-84.

14.

Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells.

Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P.

Clin Cancer Res. 1995 Aug;1(8):889-97.

15.

Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor lines.

Burger H, Nooter K, Boersma AW, Kortland CJ, van den Berg AP, Stoter G.

Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):415-24.

PMID:
9607360
16.

Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.

Ramirez PT, Gershenson DM, Tortolero-Luna G, Ramondetta LM, Fightmaster D, Wharton JT, Wolf JK.

Gynecol Oncol. 2001 Dec;83(3):543-8.

PMID:
11733969
18.

p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.

Debernardis D, Siré EG, De Feudis P, Vikhanskaya F, Valenti M, Russo P, Parodi S, D'Incalci M, Broggini M.

Cancer Res. 1997 Mar 1;57(5):870-4.

19.

Mechanism of growth-inhibitory effect of cisplatin on human pancreatic cancer cells and status of p53 gene.

Seki T, Ohba N, Makino R, Funatomi H, Mitamura K.

Anticancer Res. 2001 May-Jun;21(3B):1919-24.

PMID:
11497278
20.

The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2.

Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS.

Oncogene. 1995 Oct 5;11(7):1217-28.

PMID:
7478541

Supplemental Content

Support Center